ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / BYSI / forecast
BCTX (40) ABVC (32) CPHI (35) CELU (26) ⌘ Pro Terminal →

BeyondSpring Inc. (BYSI) 12-Month Stock Forecast & Price Target Cone

$0.81 +25.18% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.85

BeyondSpring Inc. (BYSI) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $26.5M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BYSI Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BYSI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, BeyondSpring Inc. (NASDAQ: BYSI) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $0.81 (+25.18% 1D, market cap $26.5M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, BYSI ranks #545 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BYSI compare to BCTX and ABVC in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BYSI carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BCTX (BriaCell Therapeutics Corp.) holds a D- grade (40/100 RQD, P/E N/A, ROIC —, cap $26.5M) and ABVC (ABVC BioPharma Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $26.7M). Among the 5-stock peer group, BYSI leads on earnings multiple (N/A) while CPHI leads on capital efficiency (-11.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BYSI?
▼

Per BYSI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001677940), BeyondSpring Inc. generated $25.0M in revenue (+2.2% YoY), -$1.0M in net income, and -$19.8M in free cash flow against $25.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.85 (+4.34%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510037
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D
Cash (4)Whales (8)SEC (10)Macro (10)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-9.9% Base Target
$3 Bull$1 Base$1 Bear
📬 FREE BYSI RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BYSI)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (37/100 Composite)
🔍 WHY BYSI SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (27% of score)

FRED Regime × Technicals: 19% of 52W Range • RSI-14 at 53.4 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
29
Grade E$0.61-14.8% Next Q
Q2 (-2Q)
32
Grade E$0.52-11.5% Next Q
Q3 (-1Q)
34
Grade E$0.46+76.1% Next Q
Current
37
Grade D-$0.81-8.1% Hist 90D α
Trajectory: E (29) → D- (37)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BYSI Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BYSI currently carries a cautious 37/100 (D-) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.65) and Max Pain ($0.85) forces dealer call-delta covering toward $2.56.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BYSI• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BYSI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 37%NO 63%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your BYSI Position Size: $10,000

Shares at $0.81: 12345.7 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $0.57
$7,037
$-2,963 (-29.6%)
12M Consensus BaseTarget $0.73
$9,012
$-988 (-9.9%)
12M Bull Case BreakoutTarget $2.56
$31,605
+$21,605 (+216.0%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$174%A
Goldman SachsSector Coverage LeadUNDERPERFORM$269%B
JP MorganUS Large-Cap ResearchSELL$158%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BYSI)

  • ✓Walkthrough of BYSI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
BYSI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -46.36%▼ DESCENDING CHANNEL
2026-11-03O $0.51H $0.81L $0.51C $0.81VOL 219.1K
RES: $0.96SUP: $0.39SMA50: $0.65SMA200: $1.26
$2.03$1.59$1.15$0.72$0.28RES $0.96SUP $0.39$0.812026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BYSI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BYSI Butterfly Map → + Track BYSI →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +2.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on BYSI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BYSI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BYSI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BYSI)

Health Care Rank #545 of 1015 ⚔️ BCTX vs BYSI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BYSI vs. BCTX, ABVC, CPHI, CELU)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, BeyondSpring Inc. (BYSI) ranks #545 by composite RQD confidence (37/100, grade D-) and #811 by equity capitalization ($26.5M). Within this direct 5-issuer industry benchmark cohort, BYSI leads on earnings valuation at N/A trailing P/E, while CPHI leads on capital efficiency and profitability with -11.4% ROIC and -3.2% gross margin. BCTX currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with BYSI at 37/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
BYSI ACTIVE
BeyondSpring Inc.
D- 37/100 — — -35.0% +25.18% $26.5M Benchmark Subject
BCTX
BriaCell Therapeutics Corp.
D- 40/100 — — — +1.65% $26.5M /bctx-vs-bysi →
ABVC
ABVC BioPharma Inc.
E 32/100 — — -35.0% -1.99% $26.7M /abvc-vs-bysi →
CPHI
China Pharma Holdings Inc.
D- 35/100 — -3.2% -11.4% -2.98% $26.9M /cphi-vs-bysi →
CELU
Celularity Inc. (Class A)
E 26/100 — 24.4% -35.0% +0.30% $26.0M /celu-vs-bysi →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001677940 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), BeyondSpring Inc. (BYSI) reported GAAP revenue of $25.0M (+2.2% vs. FY2024 revenue of $24.5M , and -40.7% cumulative change since FY2023) , GAAP net income of -$1.0M, operating cash flow of -$19.8M, and free cash flow of -$19.8M (-18.9% YoY). On the balance sheet, BYSI closed FY2025 with $25.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $25.0M -$1.0M -$19.8M -$19.8M $25.9M —
FY2024 (FY) 2024-12-31 $24.5M -$11.1M -$16.4M -$16.7M $34.3M —
FY2023 (FY) 2023-12-31 $42.2M -$21.0M -$16.5M -$16.5M — —

3. BYSI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BYSI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, BeyondSpring Inc. (NASDAQ: BYSI) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $0.81 (+25.18% 1D, market cap $26.5M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, BYSI ranks #545 in composite RQD confidence.

How does BYSI compare to BCTX and ABVC in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BYSI carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BCTX (BriaCell Therapeutics Corp.) holds a D- grade (40/100 RQD, P/E N/A, ROIC —, cap $26.5M) and ABVC (ABVC BioPharma Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $26.7M). Among the 5-stock peer group, BYSI leads on earnings multiple (N/A) while CPHI leads on capital efficiency (-11.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BYSI?

Per BYSI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001677940), BeyondSpring Inc. generated $25.0M in revenue (+2.2% YoY), -$1.0M in net income, and -$19.8M in free cash flow against $25.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BYSI trading relative to its 50-day, 200-day, and 52-week technical levels?

BYSI last traded at $0.81 (+25.18% on volume of 1,483,066 shares), positioning the stock +24.62% above its 50-day simple moving average ($0.65) and -35.71% below its 200-day simple moving average ($1.26). Across its 52-week range of $0.42 to $2.44, BYSI sits at the 19.3% percentile with a 14-day RSI of 53.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.91).

Direct Sub-Reports: BYSI RQD Cockpit BYSI 12M Forecast BYSI Earnings & Move BYSI Dividends & DRIP BYSI Insiders & 13F BYSI Whale Options BYSI Profit Sankey BYSI News & Why
ROARABLE RATING BRIEF • RQD 37/100 (D-) ✓ SEC XBRL & RQD VERIFIED

BYSI — BeyondSpring Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

BeyondSpring Inc. (BYSI) earns a live Roarable RQD composite score of 37/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $0.81 (+25.18% 1D, market capitalization $26.5M).

  • Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (8/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

BeyondSpring Inc. Is a NASDAQ-listed issuer classified in the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry. Reported revenue is — in each of FY 2023, FY 2024, and FY 2025, indicating no reported revenue in the sourced periods.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), BeyondSpring Inc. (BYSI) reported $25.0M in annual revenue (up from $24.5M in FY2024, +2.2% YoY) and -$1.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($42.2M revenue, -$21.0M net income) through FY2025, BYSI scaled operating cash flow to -$19.8M and free cash flow to -$19.8M, backed by $25.9M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 37/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 8/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 8/20, sustained execution supports upside toward the upper end of the $0.42 – $2.44 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), BYSI carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can BYSI sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $25.0M and free cash flow of -$19.8M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is BYSI's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

BYSI Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for BeyondSpring Inc. (BYSI) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BYSI Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BYSI Bull vs. Bear Conversation Board — What's Your Call at $0.81?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BYSI 🐻 33% BEARISH CONVICTION
1. Pick Your Side on BYSI:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $0.78 (+21.9%)
📌 Pinned Debate

Price of 0.52 sits near the bottom of a $0.42 - $2.44 52-week range with a 1.0 beta, leaving room for re-rating if cash generation turn

Picked up a starter position in BYSI in my $100K Virtual Cash book at $0.64. Price of 0.52 sits near the bottom of a $0.42 - $2.44 52-week range with a 1.0 beta, leaving room for re-rating if cash generation turns positive.. Trading inside a $0.42–$2.44 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

SectorRotator 🐂 BULL

@ForensicBear Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $0.52 (-18.8%)
Spot @ $0.64

ROIC of -35%, FCF of -$19.8M against $7.8M cash, and a Piotroski F-Score of 2/9 point to a cash engine that is not yet self-funding.

Fading this rally in BYSI at $0.64. ROIC of -35%, FCF of -$19.8M against $7.8M cash, and a Piotroski F-Score of 2/9 point to a cash engine that is not yet self-funding.. With a beta of 1.0 and the stock sitting at $0.64 (52-wk range $0.42–$2.44), the easy multiple expansion is already priced in.

LIVE TAPE